Sugi Predict

Sugi Predict / Targets / SMARCA4

SMARCA4

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 · P51532 · SMARCA4 on Sugi Atlas →

33,876 patent compounds predicted against SMARCA4, 18,075 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL119685 SCHEMBL119685 0.79 8/20
SCHEMBL1400789 SCHEMBL1400789 0.68 8/20
SCHEMBL2616482 SCHEMBL2616482 0.60 8/20
Purine Purine (SCHEMBL289481) 0.56 8/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2332222) 0.56 8/20
SCHEMBL2323931 SCHEMBL2323931 0.50 8/20
SCHEMBL2323933 SCHEMBL2323933 0.50 8/20
SCHEMBL1501665 SCHEMBL1501665 0.57 7/20
SCHEMBL2637743 SCHEMBL2637743 0.57 7/20
SCHEMBL1796453 SCHEMBL1796453 0.61 6/20
SCHEMBL1794228 SCHEMBL1794228 0.58 6/20
SCHEMBL1794315 SCHEMBL1794315 0.57 6/20
SCHEMBL1794469 SCHEMBL1794469 0.56 6/20
SCHEMBL1794659 SCHEMBL1794659 0.56 6/20
Purine Purine (SCHEMBL289483) 0.55 6/20
SCHEMBL1805661 SCHEMBL1805661 0.52 6/20
SCHEMBL1798756 SCHEMBL1798756 0.52 6/20
SCHEMBL1794455 SCHEMBL1794455 0.52 6/20
SCHEMBL1795839 SCHEMBL1795839 0.50 6/20
SCHEMBL1794680 SCHEMBL1794680 0.48 6/20

Clinical trials — most relevant to SMARCA4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy PHASE2COMPLETED
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types PHASE2COMPLETED
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma PHASE1/PHASE2WITHDRAWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes nanRECRUITING
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) nanCOMPLETED
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Natural History Study of Smith-Magenis Syndrome nanACTIVE_NOT_RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Adult Spinal Muscular Atrophy (SMA) China Registry nanACTIVE_NOT_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Palliative Care in Spinal Muscular Atrophy (SMA) 1 nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SMARCA4 binder may also engage these)

ProteinNameSimilarity
Q8K1P7 — 1.000 Q8K1P7 →
Q3TKT4 — 1.000 Q3TKT4 →
A7Z019 — 1.000 A7Z019 →
SMARCA2 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 1.000 landscape →
Q6DIC0 — 0.999 Q6DIC0 →
P25439 — 0.997 P25439 →
G5EFF5 — 0.993 G5EFF5 →
Q80TZ9 — 0.992 Q80TZ9 →
Q5HZJ0 — 0.992 Q5HZJ0 →
Q6C3D7 — 0.991 Q6C3D7 →
P34333 — 0.991 P34333 →
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 0.991 landscape →
O17286 — 0.991 O17286 →
Q62901 — 0.991 Q62901 →
P34545 — 0.991 P34545 →
Q58NQ4 — 0.991 Q58NQ4 →
Q2EJA0 — 0.991 Q2EJA0 →
Q1L8J7 — 0.991 Q1L8J7 →
Q6E3D4 — 0.991 Q6E3D4 →
Q03468 — 0.990 Q03468 →
B3M301 — 0.990 B3M301 →
A0A8C0NGY6 — 0.990 A0A8C0NGY6 →
Q09228 — 0.990 Q09228 →
P97868 — 0.990 P97868 →
Q62431 — 0.990 Q62431 →
TFEB Transcription factor EB 0.990 landscape →
Q09350 — 0.990 Q09350 →
Q94LW3 — 0.990 Q94LW3 →
Q9H334 — 0.990 Q9H334 →
O35317 — 0.990 O35317 →